Early Readout on Overall Survival of Patients With Melanoma Treated With Immunotherapy Using a Novel Imaging Analysis

医学 易普利姆玛 彭布罗利珠单抗 临床试验 内科学 肿瘤科 黑色素瘤 免疫疗法 无容量 癌症 癌症研究
作者
Laurent Dercle,Binsheng Zhao,Mithat Gönen,Chaya S. Moskowitz,Firas Ahmed,Volkan Beylergil,Dana E. Connors,Hao Yang,Lin Lü,Tito Fojo,Richard D. Carvajal,Sanja Karovic,Michael L. Maitland,Gregory Goldmacher,Geoffrey R. Oxnard,Michael Andrew Postow,Lawrence Howard Schwartz
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:8 (3): 385-385 被引量:107
标识
DOI:10.1001/jamaoncol.2021.6818
摘要

IMPORTANCE: Existing criteria to estimate the benefit of a therapy in patients with cancer rely almost exclusively on tumor size, an approach that was not designed to estimate survival benefit and is challenged by the unique properties of immunotherapy. More accurate prediction of survival by treatment could enhance treatment decisions. OBJECTIVE: To validate, using radiomics and machine learning, the performance of a signature of quantitative computed tomography (CT) imaging features for estimating overall survival (OS) in patients with advanced melanoma treated with immunotherapy. DESIGN, SETTING, AND PARTICIPANTS: This prognostic study used radiomics and machine learning to retrospectively analyze CT images obtained at baseline and first follow-up and their associated clinical metadata. Data were prospectively collected in the KEYNOTE-002 (Study of Pembrolizumab [MK-3475] Versus Chemotherapy in Participants With Advanced Melanoma; 2017 analysis) and KEYNOTE-006 (Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab [MK-3475] Compared to Ipilimumab in Participants With Advanced Melanoma; 2016 analysis) multicenter clinical trials. Participants included 575 patients with a diagnosis of advanced melanoma who were randomly assigned to training and validation sets. Data for the present study were collected from November 20, 2012, to June 3, 2019, and analyzed from July 1, 2019, to September 15, 2021. INTERVENTIONS: KEYNOTE-002 featured trial groups testing intravenous pembrolizumab, 2 mg/kg or 10 mg/kg every 2 or every 3 weeks based on randomization, or investigator-choice chemotherapy; KEYNOTE-006 featured trial groups testing intravenous ipilimumab, 3 mg/kg every 3 weeks and intravenous pembrolizumab, 10 mg/kg every 2 or 3 weeks based on randomization. MAIN OUTCOMES AND MEASURES: The performance of the signature CT imaging features for estimating OS at the month 6 posttreatment landmark in patients who received pembrolizumab was measured using an area under the time-dependent receiver operating characteristics curve (AUC). RESULTS: A random forest model combined 25 imaging features extracted from tumors segmented on CT images to identify the combination (signature) that best estimated OS with pembrolizumab in 575 patients. The signature combined 4 imaging features, 2 related to tumor size and 2 reflecting changes in tumor imaging phenotype. In the validation set (287 patients treated with pembrolizumab), the signature reached an AUC for estimation of OS status of 0.92 (95% CI, 0.89-0.95). The standard method, Response Evaluation Criteria in Solid Tumors 1.1, achieved an AUC of 0.80 (95% CI, 0.75-0.84) and classified tumor outcomes as partial or complete response (93 of 287 [32.4%]), stable disease (90 of 287 [31.3%]), or progressive disease (104 of 287 [36.2%]). CONCLUSIONS AND RELEVANCE: The findings of this prognostic study suggest that the radiomic signature discerned from conventional CT images at baseline and on first follow-up may be used in clinical settings to provide an accurate early readout of future OS probability in patients with melanoma treated with single-agent programmed cell death 1 blockade.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
1秒前
盏盏完成签到,获得积分10
1秒前
2秒前
mTOR发布了新的文献求助10
3秒前
3秒前
3秒前
忆年发布了新的文献求助10
3秒前
喵喵喵完成签到,获得积分10
4秒前
隐形曼青的应助被star采纳,获得10
4秒前
icymars完成签到,获得积分10
5秒前
Voyager发布了新的文献求助10
5秒前
5秒前
盏盏发布了新的文献求助10
5秒前
科研通AI6.2的应助被N30采纳,获得10
5秒前
5秒前
6秒前
笑点低的衬衫完成签到,获得积分10
6秒前
6秒前
xurui发布了新的文献求助10
6秒前
7秒前
一二发布了新的文献求助10
7秒前
鲤鱼鑫磊发布了新的文献求助10
8秒前
Johann0124发布了新的文献求助10
8秒前
李健的应助被欢喜的芷文采纳,获得10
9秒前
tyliak关注了科研通微信公众号
9秒前
科目三的应助被LINLIN采纳,获得10
9秒前
zjx发布了新的文献求助10
11秒前
11秒前
12秒前
12秒前
梦想家发布了新的文献求助10
12秒前
王兵发布了新的文献求助10
12秒前
12秒前
无限的盼晴完成签到,获得积分10
12秒前
13秒前
无花果的应助被mTOR采纳,获得10
13秒前
感性的忆灵完成签到,获得积分10
14秒前
zzz完成签到,获得积分10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187612
求助须知:如何正确求助?哪些是违规求助? 9575734
关于积分的说明 21842594
捐赠科研通 7785476
什么是DOI,文献DOI怎么找? 3435073
关于科研通互助平台的介绍 2559478
邀请新用户注册赠送积分活动 2481952